Multiple debulking surgery and triple antifungal therapy in abdominal-cardiac- -pulmonary invasive aspergillosis Case report
Article Sidebar
Main Article Content
Abstract
Children with acute leukemia are at a high risk of invasive fungal disease, which might manifest itself as clinically-resistant entity. The objective of this paper is to present an unusual clinical case of 17-year-old patient treated for acute lymphoblastic leukemia, with early development of disseminated invasive aspergillosis, involving the abdominal, pulmonary and cardiac structures. The patient was subjected to a combined targeted double, and later triple, antifungal therapy together with several debulking surgical interventions. The clinical course indicated a highly clinically-resistant invasive fungal disease, and the treatment was unsuccessful in this case. Limited current experience in triple antifungal therapy, abdominal aspergillosis, Aspergillus endocarditis, and possible causes of failure of antifungal therapy are discussed in the paper.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Styczynski J, Czyzewski K, Wysocki M et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect 2016; 22: 179.e1-179.e10.
3. Groll AH, Castagnola E, Cesaro S et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014; 15: e327-340.
4. Tissot F, Agrawal S, Pagano L et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017; 102: 433-444.
5. Marr KA, Schlamm HT, Herbrecht R et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-89.
6. Perea S, Gonzalez G, Fothergill AW et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039-3041.
7. Petraitiene R, Petraitis V, Groll AH et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
8. Sims-McCallum RP. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. Am J Health Syst Pharm 2003; 60: 2352-2356.
9. Ibrahim AS, Gebremariam T, Luo G et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother 2011; 55: 1768-1770.
10. Davoudi S, Anderlini P, Fuller GN et al. A long-term survivor of disseminated Aspergillus and mucorales infection: an instructive case. Mycopathologia 2014; 178: 465-470.
11. Demchok JP, Meletiadis J, Roilides E et al. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses 2010; 53: 239-245.
12. Kazan E, Maertens J, Herbrecht R et al. A retrospective series of gut aspergillosis in haematology patients. Clin Microbiol Infect 2011; 17: 588-594.
13. Yeom SK, Kim HJ, Byun JH et al. Abdominal aspergillosis: CT findings. Eur J Radiol 2011; 77: 478-482.
14. Enjoji M, Ohtsukasa S, Nagano H et al. Localized small-bowel infarction caused by Aspergillus during chemotherapy for acute myeloid leukemia: report of a case. Surg Today 2008; 38: 449-452.
15. Varadi G, Svirsky O, Nagler A. Successful major surgical recovery of a patient following haploidentical stem cell transplantation for chronic myeloid leukemia in blast crisis and aspergillosis. Acta Haematol 2002; 108: 29-32.
16. Schett G, Casati B, Willinger B et al. Endocarditis and aortal embolization caused by Aspergillus terreus in a patient with acute lymphoblastic leukemia in remission: diagnosis by peripheral-blood culture. J Clin Microbiol 1998; 36: 3347-3351.
17. Ansari Aval Z, Mirhosseini SM et al. Successful surgical intervention in an unusual case of Aspergillus endocarditis with acute myeloid leukemia. Acta Med Iran 2013; 51: 506-508.
18. Attia RQ, Nowell JL, Roxburgh JC. Aspergillus endocarditis: a case of near complete left ventricular outflow obstruction. Interact Cardiovasc Thorac Surg 2012; 14: 894-896.
19. Nikolousis E, Velangi M. Two cases of aspergillus endocarditis in non neutropenic children on chemotherapy for acute lymphoblastic leukaemia. Hematol Rep 2011; 3: e7.
20. Seo GW, Seol SH, No TH et al. Acute myocardial infarction caused by coronary embolism from Aspergillus endocarditis. Intern Med 2014; 53: 713-716.
21. Verweij PE, Chowdhary A, Melchers WJ et al. Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? Clin Infect Dis 2016; 62: 362-368.
22. Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci 2015; 1354: 1-11.